Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pharm Pract. 2013 Dec;26(6):528-40. doi: 10.1177/0897190013507582. Epub 2013 Oct 18.

New therapeutic alternatives for the management of dyslipidemia.

Author information

1
St. John's University, College of Pharmacy and Health Sciences, Department of Clinical Pharmacy Practice, Queens, New York, USA and Long Island Jewish Medical Center, Department of Pharmacy, New Hyde Park, New York, USA.

Abstract

Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of coronary heart disease (CHD). Conventional therapies, such as statins, have demonstrated their ability to improve clinical end points and decrease morbidity and mortality in patients with CHD. Lomitapide (Juxtapid(®)), mipomersen (Kynamro(®)), and icosapent (Vascepa(®)) are 3 novel agents approved by the US Food and Drug Administration in the past 2 years, which offer new lipid-lowering treatment options with unique pharmacology.

KEYWORDS:

ezetimibe/atorvastatin; hypercholesterolemia; icosapent; lomitapide; mipomersen

PMID:
24142496
DOI:
10.1177/0897190013507582
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center